Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1633-1635

  Hermsen, Elizabeth D ^a   Hovde, Laurie B ^a   Konstantinides, George N ^b   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b St John's University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MUTATION; OFLOXACIN; QUINOLINES; QUINOLONES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 16244412602     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1633-1635.2005     Document Type: Article

References (15)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
2. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
3. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
4. Dong, Y., X. Zhao, B. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2581-2584.
5. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.
6. Drlica, K. 2001. A strategy for fighting antibiotic resistance. ASM News 67:27-33.
7. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
8. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341.
9. Hovde, L. B., S. E. Rotschafer, K. H. Ibrahim, B. Gunderson, E. D. Hermsen, and J. C. Rotschafer. 2003. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumonias. Diagn. Microbiol. Infect. Dis. 45:265-267.
10. Sindelar, G., X. Zhao, A. Liew, Y. Dong, T. Lu, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44:3337-3343.
11. Smith, H. J., K. A. Nichol, D. J. Hoban, and G. G. Zhanel. 2003. Stretching the mutant prevention concentration (MFC) beyond its limits. J. Antimicrob. Chemother. 51:1323-1325.
12. Tillotson, G. S., and S. J. Watson. 2001. Antimicrobial resistance mechanisms: what's hot and what's not in respiratory pathogens. Semin. Respir. Infect. 16:155-168.
13. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.
14. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33:S147-S156.
15. Zhao, X., W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica. 2003. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1023-1027.